Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition

Item Type:	Article
Title:	Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition
Creators Name:	Travis, R.C. and Key, T.J. and Allen, N.E. and Appleby, P.N. and Roddam, A.W. and Rinaldi, S. and Egevad, L. and Gann, P.H. and Rohrmann, S. and Linseisen, J. and Pischon, T. and Boeing, H. and Johnsen, N.F. and Tjonneland, A. and Overvad, K. and Kiemeney, L. and Bueno-de-Mesquita, H.B. and Bingham, S. and Khaw, K.T. and Tumino, R. and Sieri, S. and Vineis, P. and Palli, D. and Quiros, J.R. and Ardanaz, E. and Chirlaque, M.D. and Larranaga, N. and Gonzalez, C. and Sanchez, M.J. and Trichopoulou, A. and Bikou, C. and Trichopoulos, D. and Stattin, P. and Jenab, M. and Ferrari, P. and Slimani, N. and Riboli, E. and Kaaks, R.
Abstract:	We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of androstenedione, testosterone, androstanediol glucuronide and SHBG were measured in serum samples for 643 prostate cancer cases and 643 matched control participants, and concentrations of free testosterone were calculated. Conditional logistic regression models were used to calculate odds ratios for risk of prostate cancer in relation to the serum concentration of each hormone. After adjustment for potential confounders, there was no significant association with overall risk for prostate cancer for serum total or free testosterone concentrations (highest versus the lowest thirds: OR, 1.02; 95% CI, 0.73-1.41 and OR, 1.07, 95% CI, 0.74-1.55, respectively) or for other androgens or SHBG. Subgroup analyses showed significant heterogeneity for androstenedione by cancer stage, with a significant inverse association of androstenedione concentration and risk for advanced prostate cancer. There were also weak positive associations between free testosterone concentration and risk for total prostate cancer among younger men and risk for high-grade disease. In summary, in this large nested case-control study, concentrations of circulating androgens or SHBG were not strongly associated with risk for total prostate cancer. However, our findings are compatible with a positive association of free testosterone with risk in younger men and possible heterogeneity in the association with androstenedione concentration by stage of disease; these findings warrant further investigation.
Keywords:	Prospective, Prostate Cancer, Serum, Androgen, EPIC
Source:	International Journal of Cancer
ISSN:	0020-7136
Publisher:	Wiley
Volume:	121
Number:	6
Page Range:	1331-1338
Date:	15 September 2007
Official Publication:	https://doi.org/10.1002/ijc.22814
PubMed:	View item in PubMed

Repository Staff Only: item control page